Monitoring Antiplatelet Therapy
- 1 December 2000
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 39 (6) , 445-458
- https://doi.org/10.2165/00003088-200039060-00005
Abstract
Platelet function tests measure different aspects of platelet function, which include adherence, activation, aggregation and secretion. Clinically, the goal of platelet function testing is to provide information about the platelet contribution to the risk of thrombotic or haemorrhagic events and the optimisation of antiplatelet therapy. The important clinical questions are whether an antiplatelet agent is having the desired effect on platelet inhibition (effectiveness) and whether the patient has sufficient residual platelet function to avoid bleeding (safety). The role of aspirin (acetylsalicylic acid) and thienopyridines is well established in the management of patients with coronary artery disease and in the setting of coronary interventions. The last several years have demonstrated the unequivocal effectiveness of intravenously administered platelet glycoprotein (GP) IIb/IIIa antagonists in the management of acute coronary syndromes and in the setting of percutaneous coronary interventions. With the increasing use of these GPIIb/IIIa antagonists, it is becoming more important clinically to measure platelet inhibition with these agents. This paper reviews major techniques and instrumentation for platelet monitoring and discusses the goals of the best method.Keywords
This publication has 43 references indexed in Scilit:
- Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of ThromboelastographyArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous RevascularisationDrugs, 1999
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- PFA-100™ System: A New Method for Assessment of Platelet DysfunctionSeminars in Thrombosis and Hemostasis, 1998
- A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized PatientsAnesthesia & Analgesia, 1997
- A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized PatientsAnesthesia & Analgesia, 1997
- Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptorsJournal of the American College of Cardiology, 1995
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionThe American Journal of Cardiology, 1995
- Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIaBlood Coagulation & Fibrinolysis, 1993
- An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's ThrombastheniaBritish Journal of Haematology, 1974